Lion Point Capital’s Jasper Therapeutics JSPR Stock Holding History

Lion Point Capital’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$196K	Hold	465,000	–	–	0.94%	31
2026 Q1	$407K	Hold	465,000	–	–	2.44%	16
2025 Q4	$851K	Buy	465,000 +66,442	+17%	+$133K	4.4%	5
2025 Q3	$949K	Buy	398,558 +252,058	+172%	+$764K	5.39%	4
2025 Q2	$813K	Hold	146,500	–	–	5.52%	9
2025 Q1	$630K	Buy	146,500 +114,500	+358%	+$762K	4.02%	12
2024 Q4	$684K	Hold	32,000	–	–	3.58%	12
2024 Q3	$602K	Hold	32,000	–	–	1.34%	17
2024 Q2	$726K	Hold	32,000	–	–	1.32%	17
2024 Q1	$940K	Buy	+32,000	New	+$568K	0.53%	17

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Lion Point Capital's JSPR Position: Q2 2026 in Review

Lion Point Capital held its Jasper Therapeutics (JSPR) position steady in Q2 2026 at 465,000 shares worth $196K. The position accounts for 0.94% of the portfolio, ranked #31.

Lion Point Capital first reported a position in JSPR in Q1 2024 and has held it in 10 quarters since. The position peaked at $949K in Q3 2025. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

Lion Point Capital held 465,000 shares of Jasper Therapeutics worth $196K as of Q2 2026.
Lion Point Capital left its Jasper Therapeutics share count unchanged in Q2 2026.
Jasper Therapeutics made up 0.94% of Lion Point Capital's portfolio in Q2 2026, its #31 holding.
Lion Point Capital first reported a position in Jasper Therapeutics in Q1 2024 and has held it in 10 quarters since.
Lion Point Capital's Jasper Therapeutics position peaked at $949K in Q3 2025.
45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Lion Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.